| Project/Area Number |
25893001
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
SAKURAI Yu 北海道大学, 薬学研究科(研究院), その他 (00707234)
|
|---|
| Project Period (FY) |
2013-08-30 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | siRNA / リポソーム / アクティブターゲティング / 血管新生阻害療法 / がん治療 / 腫瘍血管内皮細胞 / ドラッグデリバリーシステム / がん / ドラッグデリバリー |
|---|
| Outline of Final Research Achievements |
Angiogenesis is indispensable for a progression of cancer via a supplement with oxygen and nutrients. I developed a nanocarrier for delivering small interfering RNA (siRNA) to tumor endothelial cells (TECs). I called the carrier “RGD-MEND”. SiRNA is encapsulated in lipid envelope of RGD-MEND, and further cyclic RGD, which recognize TECs, is displayed on the surface of RGD-MEND. When the formulated siRNA to inhibit a growth of TECs was administered into tumor bearing-mice via the tail vein, tumor growth was significantly inhibited. In addition, mRNA expression level or the target gene was reduced by siRNA injection.
|
